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Litigation-related Research
The article by Madison et al. (1) con-
tains major omissions, errors, and mis-
statements which we feel compelled to
bring to your attention. First and fore-
most is the authors' failure to mention
the source of their funding. This study
was funded by lawyers for approximately
70 persons (including all 42 of the
"exposed subjects") (2). Rather than
being merely passive financiers of the
study, the lawyers were actively involved
in the design and administration of this
study, thus seriously compromising the
scientific value.
As a result, Madison et al. failed to
make any attempt to adjust for the many
biases such as self-selection and financial
gain. Many other persons were also in
the Crown Point area at the time ofthe
release and met the author's loose defini-
tion of "exposed." Such persons were
never contacted to determine their
health status (and hence, whether "expo-
sure" or litigation was the more impor-
tant factor). The Cooper Landing "con-
trol" group was equally biased, but in the
opposite direction, i.e., this group was
significantly healthier than the Cooper
Landing community as a whole. Of600
surveys mailed to the residents of
Cooper Landing, only 30 were initially
returned (3). Eventually, 65 persons
completed surveys, but only 29 showed
up to have blood samples drawn (4).
The authors failed to mention that they
performed a follow-up on nonrespon-
dents in the Cooper Landing area to
determine if the volunteers they used
were significantly healthier than the pop-
ulation at large (5). This follow-up sur-
vey clearly demonstrated that the 29
Cooper Landing volunteers were not at
all representative ofthe Cooper Landing
community. A number of the non-
respondents had conditions that
Broughton has stated previously affect
Tal levels and auto-antibodies (6).
Other major differences also existed
between the exposed subjects and the
control group. The Cooper Landing
controls were significantly older, did not
contain a single child (versus 15 children
in the "exposed" group), and the
formaldehyde antibodies of the control
group were measured with a different
microtiter reader than was used for the
exposed subjects (7). The questionnaires
and blood were obtained from the con-
trol group during a short period of time
during the summer of 1989, whereas the
questionnaires and the respiratory infec-
tions are more prevalent (8). Different
questionnaires were administered via dif-
ferent methods to the two groups. Most
of the flaws and inadequacies in the
design and administration of the study
can be attributed to the rather unortho-
dox involvement in the study of the
plaintiffs' lawyers and a marketing
research firm (9). There was no written
protocol (10), and the questionnaires
were never validated (11) and contained
poorly designed and ambiguous ques-
tions. Inquiries from respondents about
ambiguities were handled in varying and
inconsistent ways by the market survey
firm and legal assistants, as they were
given no instructions as to how to han-
dle such inquiries (12). As originally
planned, the Cooper Landing controls
were to be randomly selected, matched
for age and sex, and administered an in-
home survey by trained interviewers
(13). These protocol requirements were
all subsequently vetoed by the plaintiffs'
attorneys (14).
The poor quality ofthe data is clearly
demonstrated by a comparison of the
subjects' responses to prior question-
naires they had completed. Regarding
potential formaldehyde exposure, 10 of
the original 54 exposed subjects gave
inconsistent answers regarding their
smoking status, and 13 exposed subjects
gave inconsistent answers as to whether
they had ever lived in a mobile home.
Madison et al. reported that only seven
Crown Point residents had ever lived in
mobile homes. However, the original
questionnaires administered by Madison
et al. show that 24 subjects had lived in
mobile homes (15) (21 of whom had
blood tests and met their criteria for
inclusion).
The authors' definition of"exposure"
is also extremely ambiguous. When
Madison et al. originally presented these
data during the litigation, they included
50 persons in the exposed group for
whom they had blood test results (49
with F-HSA antibody results) (16).
During the course of their deposition
testimony, the authors learned that as
many as 13 of their original 50
"exposed" subjects were either away
from Crown Point (one was unborn) at
the time of the release or did not even
move into Crown Point until more than
a year after the incident (17). The
authors have excluded eight persons
(presumably because they were trying to
exclude such "unexposed" persons).
However, they nowhere discuss how
they excluded such persons or how
"exposure" was defined, and it appears
that at least five "unexposed" persons are
still included in the group of exposed
subjects.
The formaldehyde and trimethyl-
amine (TMA) data cited are equally mis-
leading. The "exposure" data the authors
presented for the first 48 hours (0.1-5.0
ppm) was based not upon measurements
but rather a dispersion model performed
three-and-a-halfyears after the release by
an "expert" retained byplaintiffs' lawyers
(18). We found major flaws in this
model and the assumptions used for it.
Most important, it did not fit the real
data that were available. For example,
the model predicted that subjects were
exposed to mean levels of2.0 to 5.0 ppm
(with peaks as high as 500 ppm) for
nearly 24 hours; however, few subjects
reported any odor or discomfort during
this period. Actual measurements made
hours after the release by various inde-
pendent labs contacted by the railroad
strongly suggest the inaccuracy of the
model-not a single formaldehyde mea-
surement out ofmore than 100 exceeded
0.1 ppm. The authors report that TMA
levels exceeded 0.2 ppm. This is com-
pletely untrue. Of over 100 TMA mea-
surements taken indoors in the days after
the release, the majority were negative,
and none exceed 0.2 ppm. All outdoor
measurements other than two taken in
the plume itselfwere negative (19).
The clinical laboratory techniques
used also were a source oferrorwhich ren-
der the data unreliable and make any
comparison uninterpretable. The differ-
ence between the different microtiters
used on the two groups is an obvious con-
founding factor (20). None ofthe Crown
Point plaintiffs tested on the newmachine
were positive, whereas 58% of the plain-
tiffs tested on the old machine were posi-
tive, aclearlysignificant difference:
Old Machine
New Machine
No. Tested
33
18
% Positive
58%
0%
In fact, if the comparison is limited to
the individuals tested only on the new
machine, there are more individuals with
positive formaldehyde antibodies in
Cooper Landing than in Crown Point.
Another major flaw in the formaldehyde
antibody test is that the formaldehyde-
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HSA samples contained two-and-a-half
times as much HSA as the pure HSA
blanks (21). None of these subjects was
given more than one blood test to assess
the reproducibility of any of these tests.
We learned through the California
Department of Health Services that
blood samples submitted by a Michigan
doctor to this laboratory for formalde-
hyde antibody testing and split into
duplicates yielded inconsistent results
(22). We, therefore, as part ofthe litiga-
tion investigation, undertook a double-
blind study to determine the repro-
ducibility of several tests including the
autoimmune antibody tests. Samples of
blood were drawn from 20 persons and
split into triplicate and submitted blind-
ly to Broughton's laboratory. Of the 20
blood samples submitted, eight (40%)
yielded autoimmune antibody results
which did not agree among the split
samples (23). This inconsistency has
been confirmed by researchers at the
University ofWashington, who also sub-
mitted split samples for testing of
immunologic parameters (24). These
split samples also yielded inconsistent
results, particularly with regard to the
lymphocyte subsets (Tal positive cells)
for which the correlation coefficient was
only 0.11, with greater than 50% discor-
dance relative to the laboratory's refer-
ence ranges.
The lack of reproducibility in the
autoimmune antibody test was further
demonstrated by the authors' own data
from the Crown Point subjects and
Cooper Landing controls. Most incredi-
ble, however, is the authors' failure to
report that three ofthe Cooper Landing
Controls were initially determined to be
positive for anti-parietal cell antibodies,
but were subsequently changed to nega-
tive based upon retesting of the very
same sera only two days later (25). Also,
two anti-smooth muscle antibody results
from Cooper Landing were initially
reported as positive but switched to neg-
ative upon reanalysis only two days later
(even though one was initially a "strong
positive") (26). Even more disturbing is
the fact that only one ofthe initial nega-
tive results in the control group was
retested two days later; it turned out to
be positive upon reanalysis, but the
authors chose to report it as negative
(27)! When confronted about this under
oath, Broughton testified that he would
either have to discard these data or at a
minimum report the changing of results
prior to publication (28). For some rea-
son, he has chosen to do neither. As
recently as October 1989, Broughton
was cited by the state of California for
failing to run negative quality controls
despite his previous representations to
state inspectors that he would begin
doing so (29). [The authors' statement
that "quality assurance was performed by
positive and negative controls run simul-
taneously with the unknown samples"
appears untrue. In fact, Broughton
admitted under oath that no negative
quality control is performed on the Tal
and formaldehyde tests (30)]. Moreover,
an unlicensed technician performed the
formaldehyde antibody test in violation
ofstate regulations (31). In addition, Dr.
Broughton testified under oath that he
disagreed with a number of interpreta-
tions made by his own lab technician
and that other ofthe formaldehyde anti-
body results were suspect and should
have been rerun (32). It is disconcerting
that the author would publish these data
having acknowledged these problems.
The authors' failure to adjust for
multiple endpoint analysis is also very
misleading. More than 25 blood tests
were run on each exposed subject, most
ofwhich were normal. Madison testified
under oath that multiple endpoint analy-
sis should have been done; moreover,
when appropriate adjustments for multi-
ple comparisons were made by Madison,
none ofthe blood tests were significantly
different between the two groups (33).
Another gross misstatement is the
authors' assertion that "subjects were
referred for diagnostic testing by their
physician." Broughton testified that the
testing was ordered by the plaintiffs'
attorneys in consultation with him (34).
Another false statement in the article is
that cell viability was 90% by trypan
blue exclusion. Broughton testified
under oath that his laboratory no longer
performs cell viability testing (35) (even
though it is in the written protocol he
provides to state inspectors) (36).
Ultimately, one of the most glaring
inconsistencies is the authors' failure to
explain why only 4 of the 50 plaintiffs
tested showed evidence of exposure to
formaldehyde prior to 1987 (i.e., IgG)
when the incident occurred in February
1986. In other words, their own tests
showed that only 4 of the 50 "exposed"
subjects were actually exposed to
formaldehyde during the release. Either
their formaldehyde antibody test is not a
valid indicator ofexposure or the defini-
tion for exposure in the study was inap-
propriate.
The authors conclude that persons
such as those from Crown Point with
known chemical exposure should be
examined for autoimmunity and be
monitored for "subtle alterations in their
immune system, i.e., activation." It must
be noted that Broughton has testified
that persons who pump their own gaso-
line should be similarly monitored (37).
What can be done to prevent such
reports from appearing in scholarly jour-
nals? Environmental Health Perspectives
should seriously consider revising its edi-
torial policy to make acknowledgment of
financial support mandatory rather than
optional, as many other journals have
recently done (38). Also, closer scrutiny
oflitigation-related research (e.g., requir-
ing submission of raw data and related
testimony) might also enable reviewers to
better assess the quality and integrity of
the report under submission. Finally,
authors should clearly identify a laborato-
ry which essentially has a vested interest
in the validation ofa proprietary test. The
medical and scientific community is
already recognizing and protecting
against fraud for academic gain. We must
also protect the literature from becoming
a marketing tool for people with an inter-
est (financial or other) in supporting a
particular view or methodology.
Philip Edelman
Orange, California
Patricial Sparks
Seattle, Washington
Thomas Starr
Raleigh, North Carolina
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Faulty Conclusions
This letter is prompted by Rall's editorial
on media and science in the January issue
of EHP (102:10). Rall implies that bad
reporting is being conducted concerning
dioxin, CFCs, and asbestos. Rall concludes
by assuming that he is correct in assigning
a high level of risk to each of these sub-
jects. Accordingly, corrections need to be
made in the editorial policies of science
reporting. His remedy is to make an inter-
nal review of such policies (no doubt
chaired by himself). The purpose,
undoubtedly, would be to establish policies
consistent with Rall's point ofview. I take
exception to these conclusions and illus-
trate my point by discussing the case of
dioxin.
My criticism stems from what I consid-
er bad reporting by Rall. Any good article
needs to have complete references cited. In
the case of dioxin, the references were
incomplete, making it very difficult to
check thevalidity ofRall's conclusions. On
tracking down the study ofFingerhut et al.
[New England Journal of Medicine,
324:212 (1991)], the following conclusion
was made by the authors: "This study of
mortality among workers with occupation-
al exposure to TCDD does not confirm
the high relative risks reported for many
cancers in previous studies. . ." They fur-
ther concluded that the study established
an upper level ofrisk that could be antici-
pated in humans exposed to a high level of
TCDD. In other words, for the public at
large, the risk is very small, and the report-
ing by the New York Times (as cited by
Rall) is correct that exposure to dioxin "is
now considered by some experts to be no
more risky than spending a week sun-
bathing." To continue to keep the public
stirred up as Rall would do is most inap-
propriate. Unless, ofcourse, you were seek-
inggovernment funds for more research.
Perhaps Rall should institute his own
recommendation made in his editorial
comment and have opposite views pub-
lished simultaneously with his own. He
would quickly discover that there are a few
people who take exception to his ideas.
W. BrockNeely
EnviroSoft, Inc.
Midland, Michigan
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